CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pacira Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pacira Biosciences Inc
2000 SIERRA POINT PARKWAY, SUITE 900
Phone: (650) 242-8052p:650 242-8052 BRISBANE, CA  94005  United States Ticker: PCRXPCRX
Business Summary
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Laura A.Brege 66 1/28/2025 6/2/2011
Chief Executive Officer, Director Frank D.Lee 56 1/2/2024 1/2/2024
Chief Financial Officer Shawn M.Cross 56 10/21/2024 10/21/2024
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
MyoScience, Inc. 1600 Seaport Blvd. Redwood City CA United States
PACIRA PHARMACEUTICALS INC 3535 RIVIERA DR SAN DIEGO CA US

Business Names
Business Name
82P
Flexion Therapeutics Inc
GQ Bio Therapeutics Belgium SRL
9 additional Business Names available in full report.

General Information
Number of Employees: 790 (As of 12/31/2024)
Outstanding Shares: 46,276,241 (As of 2/25/2025)
Shareholders: 9
Stock Exchange: NASD
Federal Tax Id: 510619477
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 8, 2025